The Federal Register notice describes a draft, nonbinding 503A enforcement approach during bulks-list rulemaking, not permanent listing or FDA approval. It is not a 503B expansion. [2]
The notice was published in the October 30 Federal Register. Our follow-up at 06:39 UTC (02:39 Eastern) verified the published record. We have not established a separate effective date from the announcement's publication date. [2]
Start by deciding which question brought you here: what the policy describes, what a business plans, or what would be prescribed for you. Write that question down before following any link. This guide keeps those questions separate and leaves the older Panda Bear research dates in place.
Forms and routes
| Preparation | Route or limitation |
|---|---|
| BPC-157 acetate | Subcutaneous/intramuscular injection, oral, topical |
| Epitalon acetate | Subcutaneous/intramuscular injection; intermittent courses |
| KPV acetate | Topical, oral |
| MOTS-c acetate | Subcutaneous/intramuscular injection |
| Semax free base | Intranasal |
| TB-500 acetate | Subcutaneous/intramuscular injection |
Ten cumulative conditions
- Appendix A inclusion.
- Appendix B identity/route: sequence, structure, molecular weight/formula.
- Section 510 registered facility; valid certificate of analysis (COA): Appendix B identity/purity/potency/contaminant test results.
- Original manufacturer: section 510 registration, CGMP/FD&C compliance, physical facility address on COA. FDA-registered intermediaries document manufacturer/vendor and COA validation.
- Report products, serious adverse events regardless of causation, and quality issues to FDA and compounding/destination States. Events/quality: MedWatch; patient labeling: reporting procedures. Products: ingredient/unit strength, original manufacturer/unique facility identifier, form/route.
- Label: “This is a compounded drug product. Not for resale.”
- Only one active ingredient total, from Appendix A.
- Document adequate human oral bioavailability for the supplied oral formulation.
- Co-packaged or drug-containing delivery device: FDA 510(k)-cleared syringe only.
- Remaining FD&C requirements, sanitary compounding and patient-specific prescription.
Keep the date attached to the document
The notice addresses state-licensed pharmacies, federal facilities and licensed physicians. It describes discretion while the 503A list is developed, with possible reconsideration for safety or quality concerns. The notice itself does not establish rights. [2]
When saving a passage, keep its document title and date beside it. Add a second line for what you still need to check. That makes it easier to return to the same question after a later announcement without quietly replacing the earlier record.
Give each business its own line
FDA describes different quality requirements for different compounding settings. Drugs compounded in accordance with 503A conditions are exempt from current good manufacturing practice (CGMP) requirements; 503B outsourcing-facility drugs are not. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before marketing. [4]
Keep the original manufacturer in condition four on a separate line from the compounder. Ask the professional explaining the proposal to identify which business they mean each time they discuss a document. Record the answer and any missing detail; this guide does not inspect a certificate or certify a facility.
Read the preview before making a shopping list
Hims & Hers described Peptides+ on October 29 as an upcoming specialty. Its planned menu names Sermorelin, Glutathione, B12, NAD+ and L-carnitine, with BPC-157 and TB-500 to follow when allowable. It discusses peptides and other therapies, eligibility, independent prescribers and licensed pharmacies; its forward-looking statements are not guarantees. [3]
We have not verified dispensing, prices, geographic availability or benefits from this preview. In your notes, put an unanswered question beside each missing purchasing detail. A useful follow-up is specific: which proposed product, which service, which location and which date would the answer cover? [3]
Turn one sentence into an answerable question
Try a three-line worksheet. On the first line, copy the short statement you want clarified and name the document it came from. On the second, write the question in your own words. On the third, leave room for the reply, its author and its date.
For example, if your question is about an offer, ask the provider to describe the offer it would make to you. If your question is about a prescription, ask the clinician or pharmacist to name the preparation under discussion. Keep unanswered items visible rather than filling them from an unrelated paragraph.
Bring this page as a reading aid. We have condensed the document language for orientation, so follow the original references for the full text. Our notes are not dosing instructions, a laboratory assessment or a medical recommendation. No independent clinical review is claimed.
Reader questions
Does inclusion settle whether a product is approved?
No. FDA says compounded drugs are not approved medicines or approved generics. Its approval process and a compounding arrangement are different. Ask about the finished preparation rather than treating an ingredient name as an approval record. [4]
Does this guide confirm a pharmacy or certificate?
No. We have read policy documents and a company announcement. We have not inspected your prescription, pharmacy records or a batch certificate. Keep those checks with the responsible professionals and ask them to explain any document they provide.
Where should a question about treatment go?
FDA advises discussing medication questions and individual circumstances with a healthcare professional. Take the proposed product and your unanswered questions to that conversation; do not use this policy guide to choose or change treatment. [4]
Sources
- HHS peptide policy
HHS · Checked
- Draft-policy availability notice
Federal Register · Checked
- Expanding Safe Access to Peptides
Hims & Hers · Checked
- Compounding questions and answers
FDA · Checked